Summary
EudraCT Number: 2005-005987-94
Sponsor's Protocol Code Number: GAHB-Study
National Competent Authority: Germany - BfArM 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2006-04-25
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005987-94/DE/

A. Protocol Information
A.1 Member State Concerned: Germany - BfArM
A.2 EudraCT number: 2005-005987-94
A.3 Full title of the trial: Double-blind placebo-controlled randomised trial of lamivudine in the treatment of acute hepatitis B
A.3.2 Name or abbreviated title of the trial where available: GAHB-Study
A.4.1 Sponsor's protocol code number: GAHB-Study
A.5.1 ISRCTN (International Standard Randomised Controlled Trial) number: 07772084 
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: University of Leipzig
B.1.3.4	Country: Germany
B.3.1 and B.3.2	Status of the sponsor: Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Zeffix
D.2.1.1.2 Name of the Marketing Authorisation holder: GSK
D.2.1.2 Country which granted the Marketing Authorisation: Germany
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Zeffix
D.3.4 Pharmaceutical form: Capsule, hard
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Lamivudin
D.3.9.1 CAS number: 159989-64-7
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 100 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: Information not present in EudraCT

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Capsule, hard
D.8.4 Route of administration of the placebo: Oral use

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Acute Hepatitis B 
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 8.1
E.1.2 Level: LLT
E.1.2 Classification code: 10059193
E.1.2 Term: Acute hepatitis B
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: - Is time to bilirubin < 2mg/dl shortened by the treatment with lamivudine?


E.2.2 Secondary objectives of the trial: - Is the time to clear HBV-DNA/HBeAg/HBsAg and/or development of anti-HBe/anti-
  HBs shortened by the treatment with lamivudine?
- Is the rate of HBsAg positive patients at 6 resp. 12 month lowered by the
  treatment with lamivudine?
- If initiallly abnormal: Is the time to normalization of prothrombin time (Quick ≥70%)
  and liver enzymes ALAT, ASAT shortened by the treatment with lamivudine?
- Is the rate of patients progressing to fulminant hepatitis lowered by the treatment 
  with lamivudine?
- Is the rate of Adverse and Serious Adverse Events similar in both treatment arms?
- For patients with ongoing employment relationship: Is the time to end of absence
  from work shortened by the treatment with lamivudine?

In addition, the aspects of quality of life/physical capacity resp. health economics will be adressed within two independent sub-studies.
E.2.3 Trial contains a sub-study: Yes
E.2.3.1 Full title, date and version of each sub-study and their related objectives: 1.) Analysis of single nucleotide polymorphisms, 03.04.2006, final version:
Objectives:
Is there a difference in frequency for certain SNP in patients with acute vs. chronic hepatitis B?

2.) Immune genetics in HBV, 03.04.2006, final version:
Objectives:
Are SNP on Chromosome 6 and 21 associated with severe acute hepatitis B?

3.) Immunology in acute HBV infection, 03.04.2006, final version:
Objectives:
Is viral clearance associated with an immune response against HBsAg or HBcAg?

4.) HBV-Genetics in acute HBV-Infection, 03.04.2006, final version:
Objectives:
To assess HBV variants (genotypes, precore ane basal core promotor, polymerase and preS/S-gene) as predictors for antiviral treatment efficacy in acute hepatitis B.

5.) ASSESSMENT OF QUALITY OF LIFE
Objectives:
Is the quality of life impaired by acute hepatitis B, and does this impairment persist after viral clearance?

6.) HEALTH ECONOMICS
Objectives:
Is treatment intervention with lamivudine cost effective?
Economic evaluation of lamivudine in the treatment of acute hepatitis B.



 


E.3 Principal inclusion criteria: - Acute hepatitis
- HBsAg positive
- Compensated liver function (Quick > 50%)
- Bilirubin > 5mg/dl (i.e. >85µmol/l)
- ALAT > 10 times upper normal range
- Age >= 18 years
- Time since diagnosis < 8 days
- Written informed consent of the patient
E.4 Principal exclusion criteria: - Known or obvious pre-existing liver disease (by e.g. spider naevis, ascites)
- Ongoing interferon therapy or stop of interferon less than 3 months ago
- Ongoing drug abuse
- HIV positive
- Anti-HCV or HCV-RNA positive
- Anti-HDV positive
- Renal insufficiency (creatinine >1.5mg/dl or 135µmol/l)
- Pregnant or nursing women
- Women with child bearing potential (< 2 years after last menstruation) without 
  effective contraception
- Use of oral contraception
- Patient with transplanted organs
- Any disease requiring immunosuppressive therapy, incl. cancer chemotherapy
- Any acute infectious disease requires administration of sulphonamide/ trimethoprim 
- Evidence of any other disease, metabolic dysfunction, physical examination finding, 
  or clinical laboratory finding giving reasonable suspicion of a disease or condition 
  that contraindicates use of an investigational drug, or patient at high risk from
  treatment complications
- Known hypersensitivity to any of the study drugs or its ingredients
- Current or recent (within 30 days prior to start of trial treatment) treatment with 
  another investigational drug or participation in another investigational trial
- Expected low compliance (e.g. by travel distance to trial site)
E.5 End points
E.5.1 Primary end point(s): Time until Bilirubin < 2 mg/dl

E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: Yes
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Yes
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: No
E.8.1.3 Single blind: No
E.8.1.4 Double blind: Yes
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: Yes
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 75
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 3
E.8.9.1 In the Member State concerned months: 
E.8.9.1 In the Member State concerned days: 

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception  
(For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and
did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether
or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the
database on 2006-04-25) : Yes
F.3.3.2 Women of child-bearing potential using contraception: Yes
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 140
F.4.2 For a multinational trial
F.4.2.2 In the whole clinical trial: 140
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition): Patients still HBsAg positive after 24 weeks of study therapy might be further treated openly with an antiviral drug at the discretion of the investigator. 

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2006-07-17
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2006-06-21

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2009-12-08

